stockrow
Friday 6 November 2026
Export WGS’s income statement to Excel — free account
GeneDx Holdings Corp.
WGS Healthcare Diagnostics & Research
GeneDx Holdings Corp.’s revenue for fiscal 2025 (year ended December 2025) was $427.5 million, up 40.0% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- −257.9%
- Free cash flow
- −585.6%
- Total debt
- +87.4%
Quarter to June 2026, against a year earlier
62.46
1.90
−2.95%
Follow WGS
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
8 | 6 | 3 | 4 |
| 0.84% | (7.60%) | (30.42%) | (40.80%) | ||
| 0.46% | (4.46%) | (16.33%) | (22.50%) | ||
ROIC |
3.30% | (4.42%) | (22.89%) | (27.70%) | |
Return on Tangible Assets |
1.08% | (10.25%) | (33.38%) | (47.05%) | |
Average Days of Receivables |
55.30 | 63.49 | 63.43 | 67.16 | |
Free Cash Flow per Share |
0.54 | 0.50 | (0.98) | (2.55) | |
Free Cash Flow |
15.47 | 14.26 | (28.65) | (75.80) | |
Capital Expenditures |
(17.72) | (19.02) | (19.34) | (27.09) | |
| Other line items | |||||
Cash ROIC |
3.10% | 2.70% | (5.49%) | (16.00%) | |
Accounts Receivable Turnover |
8.09 | 7.63 | 7.20 | 6.90 | |
Accounts Payable Turnover |
2.29 | 2.92 | 3.05 | 3.05 | |
Inventory Turnover |
11.44 | 10.52 | 10.82 | 9.36 | |
Average Days of Payables |
150.49 | 162.64 | 126.10 | 110.38 | |
Days of Inventory on Hand |
31.60 | 39.36 | 33.15 | 46.73 | |
Tax Rate |
(0.17) | (0.01) | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
14.69% | 16.85% | 17.90% | 18.45% | |
Selling, General and Administrative Expense of Revenue |
52.48% | 55.95% | 59.49% | 64.38% | |
Share Based Compensation of Revenue |
6.27% | 7.52% | 8.40% | 7.86% | |
Interest Coverage |
3.48 | — | (24.12) | (28.17) | |
Operating CF/Net income |
15.93 | (1.58) | 0.12 | 0.46 | |
Depreciation/Fixed assets |
0.56 | 0.55 | 0.53 | 0.49 | |
Capex/Depreciation |
(0.74) | (0.75) | (0.73) | (1.01) | |
Revenue per Share |
13.97 | 14.93 | 15.09 | 15.30 | |
Operating CF per Share |
1.15 | 1.16 | (0.32) | (1.64) | |
Capex per Share |
(0.62) | (0.66) | (0.66) | (0.91) | |
Capex to Sales |
0.04 | 0.04 | 0.04 | 0.06 |
Columns are period end dates · fundamentals updated 26 Oct 2026